Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases

European Journal of Internal Medicine

Volumn 18, Issue 6, 2007, Pages 496-500

  Aydin, Ahmet ^a   Onder, Goktug ^a   Akarca, Ulus ^a   Tekin, Fatih ^a   Tuncyurek, Muge ^a   Ilter, Tankut ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Clarithromycin resistance; Eradication; H. pylori; Pantoprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; PANTOPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA EXTRACTION; DRUG EFFICACY; DRUG SENSITIVITY; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT DURATION; VOMITING;

EID: 34548483886     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.02.018     Document Type: Article

References (31)

1. Malfertheiner P., Megraud F., O'Morain C., Hungin A.P., Jones R., Axon A., et al. Current concepts in the management of H pylori infection the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180
2. Tankovic J., Lamarque D., Lascols C., Soussy C.J., and Delchier J.C. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Pathol Biol 49 (2001) 528-533
3. Calvet X., Garcia N., Lopez T., and Gispert J.P. A metaanalysis of short versus long therapy with a proton pomp inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 14 (2000) 603-609
4. Kadayýfci A., Buyukhatipoglu H., Koruk M., and Simsek I. Türkiye'de H pylori eradikasyonunda PPI, Amoksisilin ve Klaritromisin tedavisinin etkinligi; Meta-analiz. Turk J Gastroenterol 15 suppl 1 (2004) 5
5. Meyer J.M., Silliman N.P., Wang W., and Siepman N.Y. Risk factors for Helicobacter pylori resistance in the United States: the SHARP study, 1993-1999. Ann Intern Med 136 (2002) 13-24
6. Houben M.H.M.G., van de Beek D., Hensen E.F., Craen A.J., Rauws E.A., and Tytgat G.N. A systematic review of Helicobacter pylori eradication therapy, the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 13 (1999) 1047-1056
7. Broutet N., Tchamgoue S., Pereira E., Lamouliatte H., Salamon R., and Megraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 17 (2003) 99-109
8. Taylor D.E., Ge Z., Purych D., Lo T., and Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother 41 (1997) 2621-2628
9. Tomb J.F., White O., Kerlavage A.R., Clayton R.A., Sutton G.G., Fleischmann R.D., et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 (1997) 539-547
10. Hulten K., Gibreel A., Skold O., and Engstrand L. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother 41 (1997) 2550-2553
11. Occhialini A., Urdaci M., Doucet-Populaire F., Bebear C.M., Lamouliatte H., and Megraud F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 41 (1997) 2724-2728
12. Stone G.G., Shortridge D., Flamm R.K., Versalovic J., Beyer J., Idler K., et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter 1 (1996) 227-228
13. Versalovic J., Osato M.S., Spakovsky K., Dore M.P., Reddy R., Stone G.G., et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 40 (1996) 283-286
14. Khan R., Nahar S., Sultana J., Ahmad M.M., and Rahman M. T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh. Antimicrob Agents Chemother 48 (2004) 3567-3569
15. van Doorn L.J., Glupczynski Y., Kusters J.G., Mégraud F., Midolo P., Maggi-Solcà N., et al. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother 45 (2001) 1500-1504
16. Versalovic J., Shortridge D., Kibler K., Griffy M.V., Beyer J., Flamm R.K., et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 40 (1996) 477-480
17. McLoughlin R., Racz I., Buckley M., O'Connor H.J., and O'Morain C. Therapy of Helicobacter pylori. Helicobacter 9 Suppl 1 (2004) S42-S48
18. Thyagarajan S.P., Ray P., Das B.K., Ayyagari A., Khan A.A., Dharmalingam S., et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol 18 (2003) 1373-1378
19. Vasquez A., Valdez Y., Gilman R.H., McDonald J.J., Westblom T.U., Berg D., et al. Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. Clin Microbiol 34 (1996) 1232-1234
20. Vakil N., Hahn B., and McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 93 (1998) 1432-1435
21. Debets-Ossenkopp Y.J., Herscheid A.J., Pot R.G., Kuipers E.J., Kusters J.G., and Vandenbroucke-Grauls C.M. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in the Netherlands. J Antimicrob Chemother 43 (1999) 511-515
22. Crone J., Granditsch G., Huber W.D., Binder C., Innerhofer A., Amann G., et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr 36 (2003) 368-371
23. Cabrita J., Oleastro M., Matos R., Manhente A., Cabral J., Barros R., et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 46 (2000) 1029-1031
24. Kato M., Yamaoka Y., Kim J.J., Reddy R., Asaka M., Kashima K., et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 44 (2000) 2214-2216
25. Eun C.S., Han D.S., Park Y.J., Jeon Y.C., Hahm J.S., Kim K.S., et al. Changing pattern of anti-microbial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol 38 (2003) 436-441
26. Boyanova L., Mentis A., Gubina M., Rozynek E., Gosciniak G., Kalenic S., et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Europa. Clin Microbiol Infect 8 (2002) 388-396
27. Aydin A., Buke C., Akiner C., Karasu Z., Demir A., and Gunhan C. Helicobacter pylori nin klaritromisine duyarliligi azaliyor mu. Turk J Gastroenterol 9 suppl 1 (1998) 55
28. Onder G.F., Aydin A., Akarca U.S., Ozutemiz O., and Ilter T. Ulkemizde Helicobacter pylori nin klaritromisine direncinin real-time PCR yontemi ile arastirilmasi. Turk J Gastroenterol 15 suppl 1 (2004) 40
29. Calvet X., Gene E., Lopez T., and Gispert J.P. What is the optimal length of proton pump inhibitor-based triple therapies for H pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther 15 (2001) 1067-1076
30. Gisbert J.P., Khorrami S., Calvet X., and Pajares J.M. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 16 (2004) 89-99
31. Louw J.A., van Rensburg C.J., Hanslo D., Grundlings H.D., Girdwood A.H., and Marks I.N. Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. Aliment Pharmacol Ther 12 (1998) 545-550